TrialCardiovascular diabetology2014

Safety and tolerability of canakinumab, an IL-1β inhibitor, in type 2 diabetes mellitus patients: a pooled analysis of three randomised double-blind studies.

Campbell Howard et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.